Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Durvalumab plus vaccine therapy demonstrated evidence of preliminary antitumor activity without substantial additive toxicity in BCG-unresponsive NMIBC.

Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC

First-line paromlimab/tuvonralimab plus chemotherapy with or without bevacizumab was active in recurrent/metastatic cervical cancer.

Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer

BMS-986253 plus nivolumab/ipilimumab failed to improve responses or PFS in advanced melanoma after progression on or after a checkpoint inhibitor.

BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy

Tremelimumab plus paclitaxel induced responses in metastatic urothelial cancer after progression on platinum and an immune checkpoint inhibitor.

Tremelimumab Plus Paclitaxel Generates Responses in Refractory Metastatic Urothelial Cancer

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Emiltatug ledadotin produced positive initial phase 1 data in breast, ovarian, and endometrial cancer, as well as adenoid cystic carcinoma type 1.

Emiltatug Ledadotin Generates Positive Initial Data in Advanced/Metastatic Solid Tumors

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Data from a phase 2 trial demonstrated that abenacianine is a safe investigational tumor-targeted fluorescent imaging agent for tumors in the lung.

Abenacianine Wins FDA Fast Track Designation for Tumor Visualization in the Lung

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

Christopher Graham, MD, details how axatilimab has changed the care of cGVHD and highlights considerations with axatilimab, belumosudil, and ruxolitinib.

Axatilimab Shakes Up cGVHD Treatment and Looks to Move to Earlier Line in Paradigm 

Lucio Miele, MD, PhD of LSU has been appointed as director of the LSU-LCMC Health Cancer Center.

LSU Health Professor, Dr. Lucio Miele, Appointed as Director of LSU-LCMC Health Cancer Center

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

CME Opportunities

Specialty

1rem

primary

View

Treatment and Management of Lung Large Cell Neuroendocrine Carcinoma (LCNEC)  

Lung LCNEC Diagnostic Challenges

Do you encounter challenges with performing molecular or pathology testing?

If you are unable to perform testing, how do you determine your treatment plan?

Videos

Panelists discuss how the management of lung large cell neuroendocrine carcinoma (LCNEC) involves a multidisciplinary approach, focusing on molecular characterization, biomarker testing, and emerging treatment options, including novel targeted therapies and ongoing clinical trials.

Panelists discuss how lung large cell neuroendocrine carcinoma (LCNEC) is characterized by its biology, incidence, risk factors, clinical presentation, and prognosis, while addressing the challenges, unmet needs, and the trial data required to guide testing and treatment guidelines for this rare cancer.

Lung Large Cell Neuroendocrine Carcinoma: A Rare but Aggressive Disease Intro

Panelists discuss how the characterization and classification of lung large cell neuroendocrine carcinoma (LCNEC) has evolved over the past decade, highlighting the clinical heterogeneity of these tumors and how it is navigated in clinical practice.

An Overview of the Molecular Characterization of Lung LCNEC

Panelists discuss how lung large cell neuroendocrine carcinoma (LCNEC) is diagnosed, including the challenges associated with its differential diagnosis.

The Pathological Diagnosis of Lung LCNEC 

Panelists discuss how biomarker testing for lung large cell neuroendocrine carcinoma (LCNEC) is approached, covering the frequency and types of tests used, such as NGS, the timing of DLL3 testing, and the factors influencing the choice between fine needle aspirate and other biopsy techniques.

Biomarker Testing Strategies for Lung LCNEC 

Panelists discuss the factors that influence the decision to perform a fine needle aspirate vs an incisional biopsy, whether testing is conducted in-house or at a central laboratory, and how the results of these tests impact the treatment plan for patients with lung large cell neuroendocrine carcinoma (LCNEC).

Biopsy Best Practices: Diagnosing Lung LCNEC

Panelists discuss the challenges encountered with molecular or pathology testing for lung large cell neuroendocrine carcinoma (LCNEC) and how treatment plans are determined when testing is not feasible.

Panelists discuss the vital multidisciplinary coordination needed to optimize care for patients with lung large cell neuroendocrine carcinoma (LCNEC), including the roles of various specialists, ensuring alignment on diagnosis, risk assessment, and treatment goals, and the importance of involving the patient in these discussions.

A Multidisciplinary Approach to Managing Lung LCNEC

Panelists discuss the typical treatment approach for patients with lung large cell neuroendocrine carcinoma (LCNEC), the patient-specific factors considered in first-line treatment selection, insights from the ASCO 2024 retrospective studies on first-line systemic treatment outcomes, and key considerations for choosing a second-line treatment strategy.

Lung LCNEC Disease Histology and Prognosis

The Role of DLL3 in LCNEC of the Lung

Panelists discuss their impressions of the LANCE pilot study for atezolizumab in lung large cell neuroendocrine carcinoma (LCNEC) and its potential impact on treatment strategies.

Insights on the LANCE Pilot Study on Lung LCNEC

Panelists discuss how novel targeted therapies, such as T-cell engagers, could improve outcomes for patients with lung large cell neuroendocrine carcinoma (LCNEC) and other neuroendocrine cancers (NECs).

Novel Targeted Therapies for LCNEC of the Lung

Panelists discuss ongoing trials with BI 764532 and their potential impact on the treatment of lung large cell neuroendocrine carcinoma (LCNEC).

Overview of Studies of BI 764532 for Lung LCNEC

Panelists discuss ongoing lung large cell neuroendocrine carcinoma (LCNEC) trials involving both familiar and novel agents, including phase 2 durvalumab + EP (1L), phase 2 LCNEC-ALPINE atezolizumab + EP (1L), phase 1/2 SKYBRIDGE PT217 DLL3/CD47 bispecific antibody (2L+), and phase 1 LB2102 DLL2-directed CAR T (2L+).

Insights Into Ongoing Investigational Studies in Lung LCNEC

Panelists discuss any upcoming trials on the horizon that they are excited about in the context of lung large cell neuroendocrine carcinoma (LCNEC) treatment.

Lung LCNEC Diagnostic Challenges

EP: 1.Lung Large Cell Neuroendocrine Carcinoma: A Rare but Aggressive Disease Intro

EP: 2.An Overview of the Molecular Characterization of Lung LCNEC

EP: 3.The Pathological Diagnosis of Lung LCNEC

EP: 4.Biomarker Testing Strategies for Lung LCNEC

EP: 5.Biopsy Best Practices: Diagnosing Lung LCNEC

EP: 6.Lung LCNEC Diagnostic Challenges

EP: 7.A Multidisciplinary Approach to Managing Lung LCNEC

EP: 8.Lung LCNEC Disease Histology and Prognosis

EP: 9.The Role of DLL3 in LCNEC of the Lung

EP: 10.Insights on the LANCE Pilot Study on Lung LCNEC

EP: 11.Novel Targeted Therapies for LCNEC of the Lung

EP: 12.Overview of Studies of BI 764532 for Lung LCNEC

EP: 13.Insights Into Ongoing Investigational Studies in Lung LCNEC

EP: 14.Potential Next-Generation Therapies for Lung LCNEC

Latest Conference Coverage